The Trump ad­min­is­tra­tion said on Wednes­day it will con­sid­er “op­por­tu­ni­ties to bring greater trans­paren­cy” to the ...

Zentalis Pharmaceuticals is axing about 40% of its staff and doubling down on advancing its only pipeline candidate as part ...

A Delaware judge issued a split ruling in a bizarre legal squabble over the IPO plans of Aurion Biotech, which should allow ...

President Donald Trump’s communications and travel freeze at HHS may be part of the reason an upcoming FDA advisory committee ...

Novo Nordisk is asking a federal appeals court to make haste on its case challenging the Inflation Reduction Act's drug ...

FDA expands Ozempic label to include kidney disease benefits in type 2 diabetes patients. Novo Nordisk's drug can now be ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer ...

KFF analysis highlights that ACA marketplace insurers denied 19% of claims. Less than 1% of denials were appealed, and ...

Robert F. Kennedy Jr. will sit before a Senate committee on Wednesday and provide the first substantive glimpse into how he ...

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson for the company confirmed to Endpoints News.

Leap Therapeutics reported mixed results on Tuesday for an experimental treatment in gastric and colorectal cancer, announcing it is only moving forward with the latter indication. The biotech’s ...